1996
Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas.
Piepmeier J, Susan Christopher R, Spencer D, Byrne T, Kim J, Knisel J, Lacy J, Tsukerman L, Makuch R. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996, 38: 872-8; discussion 878-9. PMID: 8727811, DOI: 10.1097/00006123-199605000-00002.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGross total resectionChronic epilepsySupratentorial low-grade astrocytomasNatural historyGross total tumor resectionImmediate postoperative radiotherapyExtent of surgerySurvival of patientsTen-year survivalPopulation of patientsUse of radiotherapyRisk of recurrenceHigh-grade lesionsLength of survivalMore malignant tumorsTypes of symptomsAggressive surgeryPostoperative radiotherapyPreoperative symptomsConsecutive patientsBetter prognosisTumor recurrenceTumor resectionMalignant tumors
1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchMeSH KeywordsBone NeoplasmsColorectal NeoplasmsCreatinineCyclosporinsDrug EvaluationFemaleHumansLiver NeoplasmsLung NeoplasmsMaleNeoplasm Recurrence, LocalPeritoneal NeoplasmsSurvival RateConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDose
1990
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrials
1985
Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
Johnson B, Ihde D, Bunn P, Becker B, Walsh T, Weinstein Z, Matthews M, Whang-Peng J, Makuch R, Johnston-Early A. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Annals Of Internal Medicine 1985, 103: 430-8. PMID: 2992337, DOI: 10.7326/0003-4819-103-3-430.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainCarcinoma, Small CellCombined Modality TherapyFemaleFollow-Up StudiesHematologic DiseasesHumansLung NeoplasmsMaleMemory DisordersMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRadiotherapyRespiratory Function TestsConceptsSmall cell lung cancerLung cancerCombination chemotherapyEvidence of cancerCancer-free survivalCell lung cancerCranial irradiationAggressive therapyLate toxicityUnrelated causesLate relapseTherapeutic trialsCancer 5PatientsPotential cureThirty-monthCancerChemotherapyRelapseCureChronic toxicityMonthsSurvivalEleven yearsToxicity
1983
Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapse
1981
Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial
Fisher R, Terry W, Hodes R, Rosenberg S, Makuch R, Gordon H, Fisher S. Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial. Surgical Clinics Of North America 1981, 61: 1267-1277. PMID: 7031934, DOI: 10.1016/s0039-6109(16)42582-x.Peer-Reviewed Original ResearchMeSH KeywordsBCG VaccineCell LineClinical Trials as TopicFemaleHumansMaleMelanomaMitomycinsNeoplasm Recurrence, LocalNeuraminidaseRandom AllocationSemustineSkin NeoplasmsTime FactorsConceptsBacille Calmette-GuerinDisease-free intervalAdjuvant immunotherapyClinical trialsMalignant melanomaStage I malignant melanomaStage II melanomaSurvival of patientsNational Cancer InstituteOverall survivalPostsurgical patientsMethyl-CCNUCalmette-GuerinCancer InstituteMelanoma cellsMelanomaFurther treatmentPreliminary reportImmunotherapyChemotherapyPatientsTrialsSurvivalSignificant improvement